Treatment de-escalation and escalation strategies in HER2-positive breast cancer

TILs as a prognostic biomarker for treatment de-escalation in HER2-positive breast cancerПодробнее

De-escalation and escalation strategies for HER2+ breast cancerПодробнее

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemoПодробнее

How to treat HER2 positive BREAST CANCER? The 2023 approach by Dr Loay KASSEMПодробнее

HER2+ Breast Cancer Deep Dive into the Science Behind the TreatmentПодробнее

SHE: "Shaping HER 2 Evolution" MeetingПодробнее

Systemic therapy in operable HER2 positive breast cancerПодробнее

16 Dec 2022 Webinar IACT & Breast GlobalПодробнее

Education Session: "Escalating and de-escalation - titrating the right regimen in early stage"Подробнее

Emerging Strategies in Breast Cancer Care Before, During and After SurgeryПодробнее

PHERGain: chemo de-escalation using F-PET in HER2+ breast cancerПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Meisel & Dr. SolimanПодробнее

Advances in Breast Cancer: Adjuvant Therapy Escalation and De-escalation: What is the future?Подробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. SchwartzbergПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Hope S. RugoПодробнее

Next steps in breast cancer: de-escalation & immunotherapyПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Reshma MahtaniПодробнее

2021 ASCO Direct St. Louis | Early Stage Breast Cancer Summary | Dr. Cynthia MaПодробнее

De-Escalating Care in Breast Cancer: A Surgeon’s PerspectiveПодробнее